These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18991579)

  • 1. Current drug metabolism.
    Kerns EH
    Curr Drug Metab; 2008 Nov; 9(9):845-6. PubMed ID: 18991579
    [No Abstract]   [Full Text] [Related]  

  • 2. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and toxicokinetics of bio-pharmaceuticals: technical problems.
    Kawai M
    J Toxicol Sci; 1996 Dec; 21(5):535-7. PubMed ID: 9035067
    [No Abstract]   [Full Text] [Related]  

  • 4. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 5. Microdosing for reduction of the time and resources for drug development.
    Sudo K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging technologies for the study of drug metabolism and pharmacokinetics.
    Hsieh Y
    Curr Drug Discov Technol; 2010 Sep; 7(3):141-2. PubMed ID: 20843297
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 10. Drugs and the liver.
    Reidenberg MM; Breckenridge A
    Clin Pharmacol Ther; 1998 Oct; 64(4):353-4. PubMed ID: 9797790
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug metabolism and pharmacokinetics in support of drug design.
    Tang W; Lu AY
    Curr Pharm Des; 2009; 15(19):2170-83. PubMed ID: 19601821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 16. 21st century drug development: advances, opportunities and challenges.
    Bhogal N
    Altern Lab Anim; 2009 Sep; 37(4):335-9. PubMed ID: 19807207
    [No Abstract]   [Full Text] [Related]  

  • 17. Goals, design, timing, and future opportunities for nonclinical drug metabolism studies.
    Miwa GT
    Toxicol Pathol; 1995; 23(2):131-5. PubMed ID: 7569666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational chemistry as an integral component of lead generation.
    Roche O; Guba W
    Mini Rev Med Chem; 2005 Jul; 5(7):677-83. PubMed ID: 16026314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICH discussion on pharmacokinetics and toxicokinetics and contributors.
    Ohno Y
    Drug Metab Pharmacokinet; 2013; 28(5):379-82. PubMed ID: 24162438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.